Congratulations to our Drs. Albert Koong and Katy Rezvani for being elected to @nam.edu, one of the nation’s most prestigious organizations in health and science. Read more about this honor and their contributions to cancer care and research. @ackoongmdphd.bsky.social #OncSky #EndCancer

UT MD Anderson’s Albert Koong and Katy Rezvani elected to the National Academy of Medicine

Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the prestigious National Academy of Medicine for breakthrough discoveries and research that have helped shape cancer care and research.

spr.ly

Ahead of #ASTRO26, our Prajnan Das, M.D., breaks down the top abstracts being presented by UT MD Anderson researchers and shares what he believes will impact patient care. @lfspurr.bsky.social #EndCancer

ASTRO 2026: Top 4 abstracts advancing radiation therapies

Radiation oncology leader Prajnan Das, M.D., shares selections for the top abstracts that will be presented by UT MD Anderson researchers at this year’s American Society for Radiation Oncology (ASTRO) Annual Meeting.

spr.ly

Get to know UT MD Anderson's Chief Scientific Officer, Dr. Albert Koong. He shares what led him to UT MD Anderson, about his lab's investigations into the tumor microenvironment and what excites him about the future of research: spr.ly/6001BG9U7l @ackoongmdphd.bsky.social #OncSky #EndCancer

Getting to know Chief Scientific Officer Albert Koong, M.D., Ph.D.

Albert Koong, M.D., Ph.D., was officially appointed UT MD Anderson's Chief Scientific Officer in June 2026. He discusses his career, passions and the future of cancer research.

spr.ly

Be ready for anything. #ZambiaSafari

After receiving prostate cancer treatment at UT MD Anderson, Bob Barnes felt compelled to use his professional skills as chairman and CEO of IBC Bank-Austin to support our mission to #EndCancer. Read his story. #OncSky

Austin banking leader and prostate cancer survivor driven to support UT MD Anderson

After receiving a prostate cancer diagnosis, Bob Barnes chose UT MD Anderson for treatment. Today, the longtime community leader and chairman and CEO of IBC Bank–Austin combines his personal cancer connection with a passion for philanthropy, recently helping raise nearly $300,000 through a charity golf tournament to support UT MD Anderson’s mission.

spr.ly

Excited to serve the research community @mdanderson.bsky.social as Chief Scientific Officer. Looking forward to advancing our basic, translational and clinical research efforts to #endcancer. spr.ly/6013B8DN0h

UT MD Anderson names Albert Koong, M.D., Ph.D., chief scientific officer

The University of Texas MD Anderson Cancer Center today announced that Albert Koong, M.D., Ph.D., an internationally recognized physician-scientist, has been appointed chief scientific officer (CSO), ...

spr.ly

Pleased to share our latest review on #cuproptosis and relevance to #cancer including radiotherapy. @mdanderson.bsky.social #radonc #endcancer www.sciencedirect.com/science/arti...

Metabolic underpinnings of cuproptosis

Cuproptosis is a recently defined form of regulated cell death (RCD) driven by copper-induced mitochondrial proteotoxic stress. Distinct from other RC…

sciencedirect.com

Declining mortatlity rates in cancer, with greatest gain in lung cancer. Continued investment in research is critical for this trend to continue. #endcancer acsjournals.onlinelibrary.wiley.com/doi/10.3322/...

Cancer statistics, 2026

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes u....

acsjournals.onlinelibrary.wiley.com

Making progress on our new research building @mdanderson.bsky.social. #endcancer #OnlyPossibleHere

Inhibition of ATR and PKMYT1 induces synthetic lethality in RB1-deficient #BreastCancer. Important implications for pts resistant to CDK4/6 inhibitors. @mdanderson.bsky.social #EndCancer www.science.org/doi/10.1126/...

Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts

ATR/PKMYT1 coinhibition induces synthetic lethality in Rb1-deficient breast cancers, supporting biomarker-guided therapy.

science.org

Researchers at MD Anderson discovered a promising therapeutic pathway for a challenging subtype of acute myeloid leukemia that uses a combination of therapies. Read more: spr.ly/63320CeB4E #OncSky #EndCancer

Bingo wishes everyone a most joyous #holiday season!

Radiation induces cell death through copper overload suggesting new therapeutic strategies for cancer pts. #radonc #endancer #cuproptosis @mdanderson.bsky.social www.cell.com/cancer-cell/... www.sciencedirect.com/science/arti...

My fav #ornament.

Annual holiday ornament exchange for the ⁦‪@MDAnderson.bsky.social‬⁩ Division Heads. May the holiday season bring everyone joy and peace. #endcancer

How do you improve cancer care without reinventing the wheel? A first-of-its-kind journal launched at MD Anderson is helping teams share real-world education and quality improvement projects with clinicians around the world. Read more. spr.ly/63327CuOx1 #OncSky #EndCancer

Journal launch enables oncology education and quality improvement

An interest in process improvement projects and learning from others led radiation oncologist Shalin Shah, M.D., to help launch MD Anderson’s first academic journal, Advances in Cancer Education and Quality Improvement (ACE-QI).

spr.ly

I always enjoy getting together with this group of #radonc leaders @mdanderson.bsky.social. #endcancer

What an inspiring day to walk with our patients, colleagues, and supporters. @mdanderson.bsky.social Boot Walk to #EndCancer. Still have time to contribute #OnlyPossibleHere mdanderson.donordrive.com/participants...

Excited to attend @mdanderson.bsky.social’s Campaign to #EndCancer. Only Possible Here.

Any guesses regarding where is this location?

Parents weekend at Brown University!

Excited to share our review of metabolic cell death pathways relevant for cancer therapy. @mdanderson.bsky.social #endcancer rdcu.be/eK7vV

Exploiting metabolic cell death for cancer therapy

Nature Reviews Cancer - In this Review, Mao et al. discuss the regulation and interplay of the metabolic cell death pathways ferroptosis, disulfidptosis and cuproptosis and explore how these...

rdcu.be

Annual @mdanderson.bsky.social #radonc faculty photo. #endcancer Can you spot who is missing?

📢 Excited to share our new pub @JCO_ASCO ascopubs.org/doi/10.1200/... ✅We report late colorectal cancer dose-response models for colorectum RT dose and chemo #radonc #medphys #survivorship @MDAndersonNews

That's a wrap! Another #ASTRO25 in the books. Great catching up with everyone. See you in Boston for #ASTRO26! #radonc #endcancer @mdanderson.bsky.social

Hanging out with the @mdanderson.bsky.social #radonc residents at the after party. #ASTRO25

"MD Anderson is committed to extending our reach to improve cancer care globally," says @schmeler.bsky.social during her #ASTRO25 presentation on identifying international partners when setting up a global oncology program. Learn more: spr.ly/6013A5Rzf #EndCancer

Global Outreach

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson's appointment process, our information page may be the best place to start.

spr.ly

Find out about our latest #radonc research to #endcancer. See you at #ASTRO25.

UT MD Anderson Cancer Center@mdanderson.bsky.social · last yr.

At #ASTRO25, MD Anderson experts will present findings from the latest research into radiation oncology. Learn more: spr.ly/63320Adeji @ackoongmdphd.bsky.social #EndCancer

"Without this network of mentorship and institutional support, I would not be in the position I am today as a physician-scientist leading my own laboratory," says our Dr. Vincent Bernard-Pagan. His insights from radiation oncology training: spr.ly/63325AbA5H #OncSky #EndCancer

4 things I learned from my radiation oncology training at MD Anderson

After completing his radiation oncology residency at MD Anderson and joining the faculty, Vincent Bernard-Pagan, M.D., Ph.D., shares what he learned from his training and what sets MD Anderson apart for trainees.

spr.ly

Targeted radiation gave patients with oligometastatic kidney cancer a median of nearly 3 years without systemic therapy while maintaining high survival. A ctDNA biomarker may help personalize this approach. spr.ly/63320ADVdQ #OncSky #EndCancer

Targeted radiation helps patients with kidney cancer delay systemic therapy 

Targeted radiation helps patients with kidney cancer delay systemic therapy 

spr.ly